Ruaraidh Hill

Ruaraidh Hill

Auto-generated profile, based on publicly available information

Ruaraidh Hill

Liverpool Reviews and Implementation Group, Department of Health Data Science, University of Liverpool, Liverpool, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SVSophia G de Vries
Sophia G de Vries
ACAnne L Cremers
Anne L Cremers
CHCharlotte C Heuvelings
Charlotte C Heuvelings
PGPatrick F Greve
Patrick F Greve
BVBenjamin J Visser
Benjamin J Visser
MGMartin P Grobusch
Martin P Grobusch

30 December 2019 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
BGBrian Godman
Brian Godman
MHMainul Haque
Mainul Haque
JMJudy McKimm
Judy McKimm
MBMuhamad Abu Bakar
Muhamad Abu Bakar
JSJacqueline Sneddon
Jacqueline Sneddon
RHRuaraidh Hill
Ruaraidh Hill
Introduction: Antibiotics are indispensable to maintaining human health; however, their overuse has resulted in resistant organisms, increasing morbidity, mortality and costs. Increasing antimicrobial resistance (AMR) is a major public health threat, resulting in multiple campaigns across countries to improve appropriate antimicrobial use. This includes addressing the overuse of antimicrobials for self-limiting infections, such as upper respiratory tract infections (URTIs), particularly in lower- and middle-income countries (LMICs) where there is the greatest inappropriate use and where antibiotic utilisation has increased the most in recent years. Consequently, there is a need to document current practices and successful initiatives in LMICs to improve future antimicrobial use. Methodology: Documentation of current epidemiology and management of URTIs, particularly in LMICs, as well as campaigns to improve future antimicrobial use. Results: There is still considerable concern regarding the prescribing and dispensing of antibiotics for URTIs among LMICs. This includes considerable self-purchasing, up to 100% of pharmacies in some LMICs. However, multiple activities are now ongoing to improve future use. These incorporate educational initiatives among all key stakeholder groups, as well as legislation and other activities to reduce self-purchasing, as part of National Action Plans (NAPs). Further activities are still needed though. These include increased physician and pharmacist education, starting in medical and pharmacy schools; greater monitoring of prescribing and dispensing practices, including the development of pertinent quality indicators; and targeted patient information and health education campaigns. It is recognised that such activities are more challenging in LMICs given more limited resources and a lack of healthcare professionals. Conclusion: Initiatives will grow across LMICs to reduce inappropriate prescribing and dispensing of antimicrobials for URTIs as part of NAPs and other activities, and these will be monitored.

1 August 2007 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
CMC McLeod
C McLeod
ABA Bagust
A Bagust
ABA Boland
A Boland
PDP Dagenais
P Dagenais
RDR Dickson
R Dickson
TWT Walley
T Walley
Health Technology Assessment Volume: 11, Issue: 28, Published in August 2007

1 July 2022 in Health Technology Assessment
Verified
Journal Article
Closed access
PDF file
JRJoanne Reeve
Joanne Reeve
MMMichelle Maden
Michelle Maden
RHRuaraidh Hill
Ruaraidh Hill
ATAmadea Turk
Amadea Turk
KMKamal Mahtani
Kamal Mahtani
EREd Ranson
Ed Ranson
Background: Tackling problematic polypharmacy requires tailoring the use of medicines to individual needs and circumstances. This may involve stopping medicines (deprescribing) but patients and clinicians report uncertainty on how best to do this. The TAILOR medication synthesis sought to help understand how best to support deprescribing in older people living with multimorbidity and polypharmacy. Objectives: We identified two research questions: (1) what evidence exists to support the safe, effective and acceptable stopping of medication in this patient group, and (2) how, for whom and in what contexts can safe and effective tailoring of clinical decisions related to medication use work to produce desired outcomes? We thus described three objectives: (1) to undertake a robust scoping review of the literature on stopping medicines in this group to describe what is being done, where and for what effect; (2) to undertake a realist synthesis review to construct a programme theory that describes ‘best practice’ and helps explain the heterogeneity of deprescribing approaches; and (3) to translate findings into resources to support tailored prescribing in clinical practice. Data sources: Experienced information specialists conducted comprehensive searches in MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Web of Science, EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials), Joanna Briggs Institute Database of Systematic Reviews and Implementation Reports, Google (Google Inc., Mountain View, CA, USA) and Google Scholar (targeted searches). Review methods: The scoping review followed the five steps described by the Joanna Briggs Institute methodology for conducting a scoping review. The realist review followed the methodological and publication standards for realist reviews described by the Realist And Meta-narrative Evidence Syntheses: Evolving Standards (RAMESES) group. Patient and public involvement partners ensured that our analysis retained a patient-centred focus. Results: Our scoping review identified 9528 abstracts: 8847 were removed at screening and 662 were removed at full-text review. This left 20 studies (published between 2009 and 2020) that examined the effectiveness, safety and acceptability of deprescribing in adults (aged ≥ 50 years) with polypharmacy (five or more prescribed medications) and multimorbidity (two or more conditions). Our analysis revealed that deprescribing under research conditions mapped well to expert guidance on the steps needed for good clinical practice. Our findings offer evidence-informed support to clinicians regarding the safety, clinician acceptability and potential effectiveness of clinical decision-making that demonstrates a structured approach to deprescribing decisions. Our realist review identified 2602 studies with 119 included in the final analysis. The analysis outlined 34 context–mechanism–outcome configurations describing the knowledge work of tailored prescribing under eight headings related to organisational, health-care professional and patient factors, and interventions to improve deprescribing. We conclude that robust tailored deprescribing requires attention to providing an enabling infrastructure, access to data, tailored explanations and trust. Limitations: Strict application of our definition of multimorbidity during the scoping review may have had an impact on the relevance of the review to clinical practice. The realist review was limited by the data (evidence) available. Conclusions: Our combined reviews recognise deprescribing as a complex intervention and provide support for the safety of structured approaches to deprescribing, but also highlight the need to integrate patient-centred and contextual factors into best practice models. Future work: The TAILOR study has informed new funded research tackling deprescribing in sleep management, and professional education. Further research is being developed to implement tailored prescribing into routine primary care practice. Study registration: This study is registered as PROSPERO CRD42018107544 and PROSPERO CRD42018104176. Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 32. See the NIHR Journals Library website for further project information.

1 June 2004 in European Heart Journal
Verified
Journal Article
Closed access
RHRuaraidh A Hill
Ruaraidh A Hill
YDYenal Dündar
Yenal Dündar
ABAmeet Bakhai
Ameet Bakhai
RDRumona Dickson
Rumona Dickson
TWTom Walley
Tom Walley
To provide systematic assessment of the clinical effectiveness of drug-eluting stents (DES) versus non-DES to inform national guidance. The review was conducted according to internationally recognised methods. The search strategy identified published (7) and unpublished (7) randomised controlled trials comparing the use of DES to non-DES. Outcomes included death, acute myocardial infarction (AMI), revascularisation, event rate (composite of adverse events), and binary restenosis. Data synthesis included descriptive statistics and meta-analysis. Fourteen randomised clinical trials comparing DES to non-DES and involving 5747 patients were identified. There were reductions in event rates between DES and non-DES; odds ratio (OR) 0.63 (95% confidence interval [95% CI] 0.47, 0.84, n = 1978) for paclitaxel-eluting stents at 12 months, OR 0.30 (95% CI 0.22, 0.42, n = 1296) for sirolimus-eluting stents at 12 months. Combined event rates were inconsistently defined across trials and were primarily composed of revascularisations, possibly driven by protocol-required angiograms. DES reduced binary restenosis rates at angiogram compared to non-DES. No significant differences in rates of death or AMI were identified. The early data available indicate that DES reduce adverse cardiac events, mainly revascularisations. However, these data are limited in terms of patient numbers, length of follow-up, and method of outcome assessment. The evaluation of rapidly evolving technologies requires the inclusion of data not routinely considered for inclusion in systematic reviews of effectiveness.

9 October 2020 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
PDF file
MMMark McCartney
Mark McCartney
SNSarah Nevitt
Sarah Nevitt
ALAnnette Lloyd
Annette Lloyd
RHRuaraidh Hill
Ruaraidh Hill
RWRoss White
Ross White
RDRui Duarte
Rui Duarte
Objective: To perform a network meta‐analysis (NMA) to compare the long‐term effectiveness of mindfulness‐based cognitive therapy (MBCT) with available strategies for prevention and time to depressive relapse.Methods: Seven electronic databases were searched up to June 2019. Studies evaluated MBCT for the management of depression‐related outcomes and follow‐up assessments occurred at 12 months or longer.Results: Twenty‐three publications were included, 17 of which were randomised controlled trials (RCTs). Data from 14 RCTs including 2077 participants contributed to meta‐analysis (MA) and NMA to assess relapse of depression and 13 RCTs with 2017 participants contributed to MA and NMA for time to relapse of depression. NMAs showed statistically significant advantages for MBCT over treatment as usual (TAU) for relapse of depression (RR = 0.73, 95% CI 0.54 to 0.98) and for MBCT over TAU and placebo for time to relapse of depression (MBCT vs TAU: HR = 0.57, 95% CI 0.37 to 0.88; MBCT vs placebo: HR = 0.23, 95% CI 0.08 to 0.67). Subgroup meta‐analysis of relapse of depression by previous number of depressive episodes showed similar results between subgroups. Subgroup meta‐analysis by the use or not of booster sessions suggests these may lead to improved effectiveness.Conclusions: MBCT is more effective than TAU in the long‐term in preventing relapse of depression and has statistically significant advantages over TAU and placebo for time to relapse of depression. No statistically significant differences were observed between MBCT and active treatment strategies for rate of relapse or time to relapse of depression.